Nasdaq has suspended trading in AMAG Pharmaceuticals (NASDAQ:AMAG) pending the release of news, in this case, the outcome of today’s FDA advisory committee meeting on its application for full approval of Makena (hydroxyprogesterone caproate injection) for reducing the risk of preterm birth in women with histories of singleton spontaneous preterm birth.
The agency granted accelerated approval in February 2011.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.